The categorization of lung allograft dysfunction is changing, David Nunley, MD, clinical director of lung transplant at the University of Louisville Health Care Outpatient Center, said at the 2014 CHEST meeting in Austin, Texas.
The categorization of lung allograft dysfunction is changing, David Nunley, MD, clinical director of lung transplant at the University of Louisville Health Care Outpatient Center, said at the 2014 CHEST meeting in Austin, Texas.
For a long time the industry spoke in terms of bronchiolitis obliterans syndrome, but now providers recognize that as just one small part of allograft dysfunction and some patients no longer fit into the category, he explained.
“We’re just now re-categorizing this, but this has long-term implications for how we’re going to treat these syndromes over the coming years,” Dr Nunley said.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More